Navigation Links
Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
Date:4/2/2009

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the expected timing of the start of clinical trials with MT203, and the potential uses of MT203 and our other product candidates. You are urged to consider statements that include the words "looking forward," "ongoing," "may," "will," "believes," "potential," "expected," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K for the fiscal year ende
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
11. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015   InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" ... ("EPS"), today announced that its CGuard TM Embolic Prevention ... Prof. Piotr Musialek , at the EuroPCR ... . PARADIGM, an investigator-initiated P rospective ... roti D revascularization I n symptomatic and increased-risk ...
(Date:5/22/2015)... , May 22, 2015 AcelRx Pharmaceuticals, Inc. ... on the development and commercialization of innovative therapies for ... that interim chief executive officer Howie Rosen ... chief financial officer Tim Morris will be ... the two presentations are as follows: Jefferies ...
(Date:5/21/2015)... May 21, 2015 Research ... addition of the "Market Assessment of Respiratory ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... respiratory imaging diagnostics market in the ... . The service provides detailed analysis of ...
Breaking Medicine Technology:InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2United States and Europe Respiratory Diagnostics Market Assessment 2015 2
... 20 Cardiac Science Corporation (Nasdaq: ... ( AED ) and diagnostic cardiac monitoring devices, ... vital signs and spot check monitors ... Canada. OMRON Healthcare is a subsidiary of OMRON Corporation, the ...
... SHENYANG, China, Oct. 20 /PRNewswire-Asia-FirstCall/ -- ... leading China-based biotechnology,company focused on researching, developing, manufacturing and ... general,meeting of shareholders held on October 12, 2009. , ... shareholders re-elected Dr. Jing Lou and Mr.,Moujia Qi to ...
Cached Medicine Technology:Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 2Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 3Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 4Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 5Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 6
(Date:5/25/2015)... 26, 2015 According to the National Library ... pigmentosa , a degenerative eye disease. The National Library of ... paroxysmal kinesigenic dyskinesia , a rare disorder that causes ... K. Chan , these two diseases are more than a ... walk in his shoes with his new autobiography “ ...
(Date:5/25/2015)... The National Association of Professional Women ... a 2015-2016 inductee into its VIP Woman of the ... for leadership in biomedical engineering. NAPW is the nation's ... than 700,000 members and over 200 operating Local Chapters. ... group of professional women," said NAPW President Star Jones. ...
(Date:5/25/2015)... 25, 2015 According to a recently ... growth in hip external fixation market is driven by ... population and advancements in infection prevention technologies. As the ... are currently accounting for the largest total number of ... falls and accidents. As a result, the average selling ...
(Date:5/25/2015)... (PRWEB) May 25, 2015 Join Fiona's Soccer ... free two-hour instructional clinic. Irish National Player, Fiona O'Sullivan ... give them a taste of her coaching style. Fiona has ... Novato. Camps in Novato are at Lynwood Elmentary School (June ... Novato High School - June 6th, 2015 - 1:00-3:00pm. Bring ...
(Date:5/24/2015)... Pacific Prime has announced that they have launched the second ... of individual international health insurance. Titled: The Cost of Health Insurance ... health insurance in six top expat destinations, which are also popular ... Kong , Singapore , China , ... UK , Article 2 presents an in-depth look at ...
Breaking Medicine News(10 mins):Health News:Joseph K. Chan Finds Faith from Disability in New Autobiography 2Health News:National Association of Professional Women Inducts Lisa Ferrara, Ph.D., CEO of OrthoKinetic Technologies, Into its VIP Professional Woman of the Year Circle 2Health News:DePuy Synthes and Stryker Lead Orthopedic External Fixation Trauma Device Market Due to Increased Hip Fractures in the U.S. 2Health News:DePuy Synthes and Stryker Lead Orthopedic External Fixation Trauma Device Market Due to Increased Hip Fractures in the U.S. 3Health News:US Sports Camps and Nike Soccer Camps Offer Complimentary Instructional Clinic with Fiona's Soccer Camp 2Health News:Pacific Prime Releases 2nd Article of Cost of Health Insurance Report 2
... TUESDAY, Jan. 4 (HealthDay News) -- Just weeks after U.S. ... to treat breast cancer, a new study provides more evidence ... failure in these patients. The meta-analysis, published online Jan. ... almost 4,000 patients and found a small but significant number ...
... Researchers have produced a lasting anti-cocaine immunity in mice by ... cold virus with a particle that mimics cocaine. , ... the online edition of Molecular Therapy and funded by ... strategy might be the first to offer cocaine addicts a fairly ...
... Jan. 4 (HealthDay News) -- Elderly people who lose their ... found. The new study included more than 4,000 Japanese ... a psychiatric assessment. Compared with participants who still had many ... were much more likely to have experienced some memory loss ...
... January 2011 - Normally, cortical nerve cells or neurons reside ... neurons in the white matter, but some people with schizophrenia ... Neuronal migration errors may arise in schizophrenia as a consequence ... of aberrant cellular localization has now been studied in detail ...
... Rochelle, NY, January 4, 2011Lowering the body temperature of ... injury may reduce neurologic complications and improve outcomes. The ... has been demonstrated in national studies. According to a ... and how it is administered should depend on the ...
... (January 4, 2011) -- Cumbersome glaucoma tests requiring a ... to a home test developed by an engineer at ... involving a system of micro-force sensors, specially designed microchips, ... at the UA College of Engineering. The easy-to-use probe ...
Cached Medicine News:Health News:More Evidence Links Avastin to Heart Failure in Breast Cancer Patients 2Health News:More Evidence Links Avastin to Heart Failure in Breast Cancer Patients 3Health News:Vaccine blocks cocaine high in mice 2Health News:Vaccine blocks cocaine high in mice 3Health News:Neuronal migration errors: Right cells, wrong place 2Health News:Optimizing patient outcomes after therapeutic hypothermia for traumatic brain injury 2Health News:New glaucoma test allows earlier, more accurate detection 2
... its name from its first known site ... majority of PSA circulates bound to anti-chymotrypsin ... of PSA are elevated in patients with ... prostatitis [1-3]. In addition, PSA serum levels ...
... profitability by reducing ... simple test,sequences that ... by ancillary office ... 5 minutes. New ...
... as a Valuable Tool for Measuring ... Eye Disease. Near Test F.A.C.T. 101: ... (12.7cm x 17.78cm) Can be Hand-Held ... F.A.C.T. 201: Size 27 in ...
Adult: Letter Monocular Acuity, Binocular Astigmatism, Acuity Balance, Supression, Binocular Acuity, Fixation Desparity, Muscle Balance, Stereopsis...
Medicine Products: